irofulven has been researched along with altretamine in 1 studies
| Studies (irofulven) | Trials (irofulven) | Recent Studies (post-2010) (irofulven) | Studies (altretamine) | Trials (altretamine) | Recent Studies (post-2010) (altretamine) |
|---|---|---|---|---|---|
| 99 | 22 | 7 | 479 | 107 | 26 |
| Protein | Taxonomy | irofulven (IC50) | altretamine (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P | 1 |
1 other study(ies) available for irofulven and altretamine
| Article | Year |
|---|---|
Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Topics: Altretamine; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Synergism; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Random Allocation; Sesquiterpenes; Transcription, Genetic; Xenograft Model Antitumor Assays | 2008 |